Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML
V. Mohanty, N. Baran, Y. Huang, C. L. Ramage, L. M. Cooper, S. He, R. Iqbal, M. Daher, CTD2 Research Network, J. W. Tyner, G. B. Mills, M. Konopleva, K. Chen
This study identifies four transcriptionally distinct venetoclax-resistant clusters in AML, revealing phenotypic, genetic, and drug response differences and their implications for treatment resistance.
bioRxiv · Jan 27, 2024 · PreprintCancer Biology